Evotec's Alzheimer's drug OK in phase 1
Evotec's Alzheimer's drug OK in phase 1: "U.S. firm Evotec said Tuesday EVT 101, a potential treatment for Alzheimer's disease, looked promising in a phase 1 trial."
Previous
- Pharmaceutical Processing
- PharmaLive: Pharmexa Discontinues Phase II Trial of Breast Cancer Vaccine
- Neurochem CEO: Odds Of Kiacta Approval 'Much Higher' - Forbes.com
- New roles for old medications�-
- D-Pharm Completes Enrollment for the Phase IIb trial of DP-b99 in Acute Stroke Patients
- Lexicon gets OK to start test of Alzheimer's drug
- Transition Gets Go-Ahead for Clinical Trials of Alzheimer's Drug | INS News
- Allon Files CTA to Add Canadian Sites to Phase II Clinical Trial
- BTG completes early Alzheimers trial says started yr in strong position
- TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease
Resources
CDC: Morbidity and Mortality Weekly
Favorite podcasts
0 Comments:
Post a Comment
<< Home